| The Nasdaq sold-off for 1.4% in a down day for US markets on Thursday. The S&P 500 lost 0.8%, and the Dow slid to a 0.4% decline. The small-cap Russell 2K tumbled 2.3% in the trading session. Today, futures are pointing to another down open for US benchmarks. S&P 500 contracts are currently showing a 1.4% loss in early morning trading. The Best Lithium Stock for Less Than $1 ð
An undiscovered lithium stock trading below $0.30 per share just uncovered 8 high-quality targets on unexplored ground.
Drills are turning on later this year, but very few investors know about it yet, so this ground-floor opportunity below $0.30 won't be around much longer. It's a new breed of lithium stock, and shares could be on course to explode. Get the Name and Trading Symbol Here The British pound tumbled to a 37-year low this morning on news of a larger-than-expected tax cut financed and increased government borrowing.Chinese auditors are starting to face US inspections from the Public Company Accounting Oversight board. Inspectors will decide if firms like Alibaba [BABA], Yum China [YUMC], and others can keep their US listings. Dentsply Sirona [XRAY] - Last Close: $29.55 News of a personnel change is lifting Densply Sirona this morning. The dental equipment manufacturer announced after yesterday's closing bell that it had appointed a new Chief Financial Officer. The company recruited Integra Lifesciences COO Glenn Coleman to take the helm as CFO, and he'll start his new position on Sept. 26th. Coleman will replace interim CFO Barbara Bodem. XRAY is leading the S&P 500 with a 3.0% premarket gain. My Take: CFO is an important position, so investors were pleased to see the firm find someone to take the role on a permanent basis. However, I don't think it really changes the stock's long-term outlook. Sellas Life Sciences Group [SLS] - Last Close: $2.31 Sellas Life Sciences says it will provide a key drug update at an upcoming conference. The late-stage clinical biotech firm said this morning that it will host a poster presentation related to its CDK9 inhibitor, GFH009, at the upcoming Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO). Sellas will make its presentation on Wednesday, Sept. 28th, at 6:05 p.m., with Senior VP of Clinical Development Dragan Cicic serving as host. According to a company press release, the poster presentation characterizes the preclinical pharmacokinetic (PK) profiles of two different formulations of GFH009 maleate, pH 4.5 and pH 6.0. Shares of SLS are up 24.2% in today's premarket. My Take: It sounds like SLS is getting ready to unveil some positive data at this conference next week, and investors are positioning themselves in anticipation of the potential rally catalyst. However, it's anyone's guess whether the presentation will live up to this early hype, so don't get tricked into over-paying if you decide to get in this one. Sonendo Inc [SONX] - Last Close: $0.9071 Sonendo is making a big push higher after an early-morning announcement. The commercial-stage medical technology company unveiled a $63 million private placement in today's pre-bell trading session. New and existing investors, including Pura Vida Investments, First Light Asset Management, Blue Water Life Science Advisors, and others participated in the private placement financing. CEO Bjarne Bergheim said the new capital will shore up its balance sheet and product development. SONX is one of this morning's top performers with a 66.5% gain. My Take: Investors obviously like this deal for SONX. The company must be doing something right if it convinced so many of its backers to pony up more cash. This small-float stock could be worth your attention. Ruby Therapeutics [RUBY] - Last Close: $0.4546 Ruby Therapetics is enjoying a sharp rebound rally today. The biopharma firm has struggled since pulling the plug on two key cancer trials last week, but it's showing signs of life ahead of today's open. RUBY set a new 52-week low on Thursday, but the stock is bouncing back with sharp gains today. Earlier in the week, Ruby Therapeutics announced its CEO Pablo J. Cagnoni, M.D. will host a "fireside chat" at Guggenheim Nantucket Therapeutics Conference on Tuesday, according to a company press release. RUBY is one of today's most active premarket stocks, and it's up 30.7%. My Take: It's unclear what will be discussed at the so-called "fireside chat," but the event could be a catalyst for this beaten down stock. RUBY's decision to cancel its cancer trials really hurt investor sentiment, but it's possible the resultant declines have been overdone at this point. |
